Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Krystal Biotech, Inc.NASDAQ: KRYS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $14.16M rose 0.3% year over year, ahead of the -23.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Stock-based compensation amounted to 14.0% of revenue in FY2025, down 2.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -23.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 54.51M USD
- Year-over-year change
- +11.0%
- 4-year CAGR
- +37.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.51M | +11.0% |
| FY2024 | 2024-12-31 | 49.13M | +23.0% |
| FY2023 | 2023-12-31 | 39.93M | +20.2% |
| FY2022 | 2022-12-31 | 33.23M | +116.9% |
| FY2021 | 2021-12-31 | 15.32M | — |
Stock-Based Compensation vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 stock-based compensation of $41.53M is the 2nd largest of the 6 companies compared; the peer median is $34.64M.
- Its year-over-year change of -23.5% is the 5th highest of 6, against a peer median of -7.4%.
- Stock-based compensation amounts to 9.4% of revenue for KRYS, versus a peer median of 57.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Jun 2026 | $41.53M | -23.5% | +17.9% | 9.4% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $24.1M | -32.3% | -12.7% | — | |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| Peer median (excluding KRYS) | $34.64M | -7.4% | -5.4% | 57.3% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (22.85M) |
| Stock-Based Compensation | 15.32M | 33.23M | 39.93M | 49.13M | 54.51M |
| Change in Working Capital | 2.05M | 2.81M | (37.88M) | (14.46M) | (36.42M) |
| Accounts Receivables | 0 | 0 | (42.04M) | (62.71M) | (22.12M) |
| Inventory | 0 | 0 | (4.48M) | (11.91M) | (6.29M) |
| Accounts Payables | 712K | (1.25M) | (101K) | 1.01M | 826K |
| Other Working Capital | 1.34M | 4.07M | 8.73M | 59.15M | (8.84M) |
| Other Non-Cash Items | 1.49M | (690K) | (106.79M) | (7.12M) | (5.77M) |
| Operating Cash Flow | (47.94M) | (100.57M) | (88.8M) | 123.42M | 200.87M |
| Capital Expenditures | (68.34M) | (52.98M) | (11.8M) | (4.24M) | (11.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 435K |
| Purchases of Investments | (190.46M) | (318.78M) | (508.78M) | (457.74M) | (422.54M) |
| Sales of Investments | 32.03M | 257.68M | 503.21M | 298.54M | 375.64M |
| Other Investing Activities | 0 | 0 | 100M | 0 | 0 |
| Investing Cash Flow | (226.77M) | (114.08M) | 82.64M | (163.44M) | (58.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 355.65M | 36M | 203.5M | 32.4M | 22.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.96M) | (649K) | (749K) | (5.39M) | (13.96M) |
| Financing Cash Flow | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Effect of Forex Changes | 0 | (41K) | (156K) | (458K) | 286K |
| Net Change in Cash | 72.98M | (179.35M) | 196.43M | (13.46M) | 151.44M |
| Free Cash Flow | (116.27M) | (153.55M) | (100.6M) | 119.18M | 188.91M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.